CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

NEW YORK--(BUSINESS WIRE)--Aug 3, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803149922/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company may have misled investors about the importance of Fabric Genomics; (2) as a result, the Company’s margins would suffer; (3) the company’s average reimbursement rates were not as “durable” as previously disclosed; (4) as a result of the foregoing, the Company’s gross margins would decline; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

On May 4, 2026, the price of the Company's shares closed at $67.93. After hours, the Company disclosed that its Q1 financial results had missed for both its exome and genome lines, and cut its 2026 guidance from $540-555 million to $475-490 million.

During the related earnings call, the Company disclosed that the average reimbursement rate came in at $3,300, or $200 below expectations. It also disclosed that it had taken a goodwill impairment charge of $31.3 million as a part of the Fabric Genomics acquisition – after paying $36.5 million for the Company only a year before.

On this news, GeneDx’s share price fell over 49%, or $33.42 per share, from the close on the previous day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding GeneDx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the GeneDx class action, go to www.faruqilaw.com/WGS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the GeneDx Holdings Corp. Securities Class Action Lawsuit:

What is the GeneDx Holdings securities fraud lawsuit about?

The GeneDx Holdings securities fraud lawsuit is a federal securities class action alleging that GeneDx Holdings Corp. (NASDAQ: WGS) and its executives made false and misleading statements to investors by misrepresenting the importance and value of its Fabric Genomics acquisition, overstating the durability of its average reimbursement rates, and concealing that the Company's gross margins would decline as a result. As the truth emerged on May 4, 2026 — when GeneDx disclosed that Q1 results had missed expectations across both its exome and genome lines, cut its 2026 revenue guidance from $540–$555 million down to $475–$490 million, revealed that average reimbursement rates came in at $3,300 (approximately $200 below expectations), and disclosed a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition it had purchased for $36.5 million just one year prior — WGS shares fell over 49%, or $33.42 per share, in a single day, causing significant losses for investors.

Who may be eligible to participate in the GeneDx Holdings class action lawsuit?

Investors who purchased or acquired GeneDx Holdings (WGS) stock between April 16, 2025 and May 4, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the GeneDx securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former GeneDx employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the GeneDx Holdings lawsuit?

A lead plaintiff in the GeneDx Holdings class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any GeneDx investor who purchased WGS stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased GeneDx Holdings stock during the Class Period?

Investors who purchased GeneDx Holdings (WGS) stock between April 16, 2025 and May 4, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the GeneDx Holdings securities class action is August 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/WGS for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

CHICAGO (AP) — An American citizen shot by a Customs and Border Protection agent one year ago during a sweeping immigration crackdown in Chicago filed a lawsuit against the federal government on Monday, alleging the agent lied about the shooting and fired into her vehicle from behind.

Federal prosecutors initially accused Marimar Martinez, then 30, of using her vehicle to strike and box in agent Charles Exum’s SUV on Chicago’s southwest side on Oct. 4, 2025, during “Operation Midway Blitz.” Exum then exited his car and opened fire, leaving Martinez with seven gunshot wounds.

In the month after the shooting, prosecutors filed to dismiss the charges in a dramatic reversal of the closely watched case in the nation's third-largest city.

Her lawyers said Monday that they commissioned an expert to analyze bullet trajectories and her injuries and determined Exum wasn't in the path of her car when he opened fire. They said he had walked several feet toward her car, contrary to statements he made to the FBI, and fired off five shots in less than a second, the last from the rear side of her vehicle.

“Charles Exum told the FBI agent on that day, within hours of the shooting, that Marimar was driving her car directly at him, that he shot her five times through the windshield, and that he ceased firing once he was no longer in the path of the vehicle. Those are three objective lies that you’ll see here today,” said one of her attorneys, Chris Parente.

Parente said there were only three bullet holes in Martinez’ windshield on the right passenger side, which indicated Martinez wasn't driving toward the agent. He said the fourth shot was fired through the front passenger side window, adding another bullet hole in the back of Martinez’ car seat showed the agent fired the fifth shot from behind her.

“In what world can a U.S. law enforcement officer stand behind a car and fire his Glock service weapon through the rear passenger window at a young woman who’s crouched over the steering wheel?” Parente said.

CBP said in a statement to The Associated Press in response to the suit that Exum had been placed on administrative leave. Use-of-force incidents are “thoroughly investigated, reviewed, and presented” to an independent board, it added.

Exum is not a defendant in the lawsuit against the federal government, which was filed under the Federal Tort Claims Act and does not allow for lawsuits against individual agents. It was not known where Exum could be reached.

Body-worn camera footage from another agent in Exum's vehicle before the shooting captured the agents saying it was “time to get aggressive” and making other profanity-laced comments encouraging violence, according to the complaint.

The FBI arrested Martinez, taking her out of the hospital just hours after the shooting when she was “wheelchair bound and her bullet holes were leaking blood through her bandages,” according to the lawsuit. A judge ordered her release two days after her arrest.

Messages released by Martinez’ attorneys in February showed that former head of Border Patrol Greg Bovino had praised Exum for his “excellent service in Chicago” after the shooting. Other messages they released showed agents in a group chat congratulating Exum and calling him a “legend.”

Martinez was one several people shot in their cars by federal agents during President Donald Trump’s immigration crackdown. An immigration agent shot a Venezuelan delivery driver in his car in Austin, Texas, last month, and another shot a Colombian driver in Biddeford, Maine, in July. The Trump administration has at times justified such shootings as self-defense against people allegedly weaponizing their vehicles.

Martinez appeared with her attorneys at a news conference Monday, saying the various shootings spurred her to file suit.

“If I don’t, then who else, you know? Look at what happened to Renee and all these victims,” she said, referring to Renee Good, a woman shot dead in her vehicle by a federal agent in Minneapolis in January.

“What’s happening is not normal. We shouldn’t stay here and normalize what’s happening,” she said.

Mayes-Osterman is a corps member for The Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues.

FIEL - Demonstrators march at a protest opposing "Operation Midway Blitz" and the presence of ICE, on Sept. 9, 2025, in Chicago. (AP Photo/Erin Hooley, File)

Attorney Michael Gallagher, right, talks to media as attorney Christopher Parente, center, and Marimar Martinez, a Chicago woman who was shot by a Border Patrol agent last year, listens to him at a press conference Monday, Oct. 5, 2026, in Chicago. (AP Photo/Nam Y. Huh)

Marimar Martinez, a Chicago woman who was shot by a Border Patrol agent last year, listens to attorney Michael Gallagher at a press conference Monday, Oct. 5, 2026, in Chicago. (AP Photo/Nam Y. Huh)

Marimar Martinez, a Chicago woman who was shot by a Border Patrol agent last year, listens to attorney Michael Gallagher at a press conference Monday, Oct. 5, 2026, in Chicago. (AP Photo/Nam Y. Huh)

Marimar Martinez, a Chicago woman who was shot by a Border Patrol agent last year, listens to attorney Christopher Parente at a press conference Monday, Oct. 5, 2026, in Chicago. (AP Photo/Nam Y. Huh)

Attorney Christopher Parente, right, talks to media as Marimar Martinez, a Chicago woman who was shot by a Border Patrol agent last year, listens to him at a press conference Monday, Oct. 5, 2026, in Chicago. (AP Photo/Nam Y. Huh)

Marimar Martinez, a Chicago woman who was shot by a Border Patrol agent last year, listens to attorney Christopher Parente at a press conference Monday, Oct. 5, 2026, in Chicago. (AP Photo/Nam Y. Huh)